Researchers are developing a promising new cancer immunotherapy that could transform how certain cancers are treated.
Unlike traditional CAR T-cell therapy, which requires extracting a patient’s immune cells, modifying them in a laboratory, and then reinfusing them, this new approach works inside the body with just one injection.
The treatment builds on the concept of CAR T therapy, a powerful form of immunotherapy that enhances a patient’s T cells so they can recognize and destroy cancer cells.
While existing CAR T treatments have shown remarkable success against some blood cancers, they are expensive, time-consuming to produce, and often require patients to undergo preparatory chemotherapy, which can weaken already fragile immune systems.
The new method aims to reprogram T cells directly inside the patient’s body. Early clinical results from a small trial showed that four people with persistent multiple myeloma went into remission for several months after receiving the injection. The therapy uses targeted delivery systems to equip the immune cells with guidance mechanisms so they can home in on and eliminate cancer cells more efficiently.
This in-body reprogramming sidesteps many limitations of the traditional lab-based process, potentially speeding treatment and lowering costs. It represents a major step toward practical “one-and-done” immunotherapy options that could be more accessible to a broader range of patients.
Despite the encouraging results, the research is still in early stages. Scientists will need to follow participants over longer periods to understand how durable the immune response is and whether the approach can be applied to other cancers. If successful, this technique could reshape cancer treatment and bring powerful new therapies within reach for many more people.